Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder

References

• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville (MD): SAMHSA. Center for Behavioral Health Statistics and Quality, Editor; 2020.
   Google Scholar
• Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics, Center for Disease Control and Prevention; 2022.
   Google Scholar
• Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, and Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD001333. doi:10.1002/14651858.CD001333.pub4.
   PubMedGoogle Scholar
• Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos J-MS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K, et al. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction. 2017;112:830–37. doi:10.1111/add.13724.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32:503–17. doi:10.1080/00952990600918973.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18. doi:10.1016/S0140-6736(17)32812-X.
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188–209. doi:10.1111/add.14180.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA, et al. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. Drug Alcohol Depend. 2018;187:171–78.
   PubMed Web of Science ®Google Scholar
• Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49–57. doi:10.1016/j.neubiorev.2018.12.005.
   PubMed Web of Science ®Google Scholar
• Levin FR, Mariani JJ, Pavlicova M, Choi CJ, Basaraba C, Mahony AL, Brooks DJ, Naqvi N, Bisaga A. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. Drug Alcohol Depend. 2021;219:108482. doi:10.1016/j.drugalcdep.2020.108482.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38:187–99. doi:10.3109/00952990.2011.653426.
   PubMed Web of Science ®Google Scholar
• Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV, et al. Long-Acting Injectable Naltrexone Induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174:459–67.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend. 2015;147:122–29. doi:10.1016/j.drugalcdep.2014.11.028.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 2011;119:e23–9. doi:10.1016/j.drugalcdep.2011.05.019.
   PubMedGoogle Scholar
• Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015;154:38–45.
   PubMed Web of Science ®Google Scholar
• Sibai M, Mishlen K, Nunes EV, Levin FR, Mariani JJ, Bisaga A. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. Am J Drug Alcohol Abuse. 2020;46:289–96. doi:10.1080/00952990.2019.1700265.
   PubMed Web of Science ®Google Scholar
• Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, Dunn KE. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. Am J Addict. 2021;30:83–87. doi:10.1111/ajad.13069.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30:305–15. doi:10.1111/ajad.13135.
   PubMed Web of Science ®Google Scholar
• Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW. Safety and efficacy of lofexidine for medically managed opioid withdrawal: a randomized controlled clinical trial. J Addict Med. 2019;13:169–76. doi:10.1097/ADM.0000000000000474.
   PubMed Web of Science ®Google Scholar
• Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. J Am Pharm Assoc (2003). 2020;60:145–52. doi:10.1016/j.japh.2019.10.004.
   PubMed Web of Science ®Google Scholar
• Kahn A, Mumford JP, Rogers GA, and Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44:57–61.
   PubMed Web of Science ®Google Scholar
• Lin SK, Strang J, Su L-W, Tsai C-J, Hu W-H. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48:127–33. doi:10.1016/S0376-8716(97)00116-6.
   PubMed Web of Science ®Google Scholar
• Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50:251–54. doi:10.1016/S0376-8716(98)00040-4.
   PubMed Web of Science ®Google Scholar
• Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, Delsignore R. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001;21:11–17. doi:10.1016/S0740-5472(01)00178-7.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction. 2003;98:427–39. doi:10.1046/j.1360-0443.2003.00372.x.
   PubMed Web of Science ®Google Scholar
• Gripshover J, Kosten T. Managing opioid withdrawal in an outpatient setting with lofexidine or clonidine. Cureus. 2022;14:e27639. doi:10.7759/cureus.27639.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33;quiz 34–57.
   Web of Science ®Google Scholar
• Group TCSR. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27:1107–22.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;170–78. discussion 168-9. doi:10.15288/jsas.2005.s15.170.
   PubMedGoogle Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare; 1976.
   Google Scholar
• Litten R, Allen J, Litten RZ, Allen JP. Measuring alcohol consumption: psychosocial and biochemical methods. Totowa, NJ: The Humana Press Inc; 1992. p. 41–72. doi:10.1007/978-1-4612-0357-5.
   Google Scholar
• Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl. 2005;157–67. discussion 140. doi:10.15288/jsas.2005.s15.157.
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi:10.1136/jnnp.23.1.56.
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoact Drugs. 2003;35:253–59. doi:10.1080/02791072.2003.10400007.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2020. http://www.r-project.org/index.html.
   Google Scholar